What Researchers Are Studying
-
The GHRH Pathway
Growth-hormone-releasing hormone is produced in the brain and signals the pituitary gland to release growth hormone. Researchers study GHRH analogs to better understand this normal endocrine signaling pathway.
-
Pituitary Signaling
CJC-1295 No DAC is being studied for its interaction with receptors involved in pituitary growth-hormone signaling. Growth hormone itself is one of the measurements researchers may examine in this type of research.
-
The Growth-Hormone/IGF-1 Axis
Scientists also study the broader relationship among GHRH, growth hormone, and insulin-like growth factor 1, or IGF-1. This is a complex regulatory system, and changes in one part of the pathway do not establish a particular clinical outcome.
Quick Answer
CJC-1295 No DAC is commonly used to describe a modified GHRH analog, sometimes called Modified GRF 1-29. It is not growth hormone itself. Rather, researchers study it for its interaction with the GHRH pathway involved in pituitary growth-hormone signaling. "No DAC" means it does not contain the drug-affinity complex used in certain longer-acting CJC-1295 formulations.
At a Glance
What it is
A synthetic peptide related to growth-hormone-releasing hormone.
Why it attracts attention
Researchers study it in connection with pituitary signaling and the growth-hormone/IGF-1 axis.
What the evidence looks like
Research on GHRH analogs exists, but human evidence specific to CJC-1295 No DAC remains limited.
Important context
CJC-1295 No DAC is an investigational peptide and is not FDA-approved for any medical indication.
What We Know - and What Remains Unclear
CJC-1295 No DAC is often discussed in peptide communities because of its relationship to the GHRH pathway. But a biological mechanism is not the same as a proven health outcome.
Important questions remain about its safety, effectiveness, appropriate use, and long-term effects in humans. Anyone considering peptide therapy should have an individualized conversation with a qualified provider who can discuss current evidence, limitations, health history, medications, and other relevant considerations.
Frequently Asked Questions
Is CJC-1295 No DAC the same as growth hormone?
No. CJC-1295 No DAC is not growth hormone. It is a peptide related to growth-hormone-releasing hormone, which is involved in signaling between the brain and pituitary gland.
What does "No DAC" mean?
"DAC" stands for drug-affinity complex and is used in certain longer-acting CJC-1295 formulations. CJC-1295 No DAC does not include that modification.
Is CJC-1295 No DAC the same as CJC-1295 with DAC?
They are related but distinct formulations. The "No DAC" designation refers to the absence of the longer-acting drug-affinity complex.
Is CJC-1295 No DAC FDA-approved?
No. CJC-1295 No DAC is not FDA-approved to diagnose, treat, cure, or prevent any disease or medical condition.
Learn More About Peptide Therapy
Emerging peptide science is complicated. Advanced Mobile IV can help you understand the current conversation around CJC-1295 No DAC and other peptide therapies, the questions to ask, and whether a discussion with a qualified provider makes sense for you.
Call Advanced Mobile IV to Learn MoreThis page is for educational purposes only and is not medical advice. CJC-1295 No DAC is an investigational peptide; research is ongoing, and scientific understanding continues to evolve.